| | | | |
»áÒéÃû³Æ£ºÖйú»¯Ñ§»áµÚ30½ìѧÊõÄê»á ·Ö»áÃû³Æ£ºµÚ¶þÊ®°Ë·Ö»á£º»¯Ñ§ÉúÎïѧ |
¡¡×¢£ºPL-´ó»áÌØÑû±¨¸æ(Plenary Lecture) I-·Ö»áÑûÇ뱨¸æ(Invited) O-¿ÚÍ·±¨¸æ(Oral) P-ǽ±¨(Poster) A-×ÔÓɽ»Á÷ |
2016-07-02 |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÖÜÏè£¬Ï¯Õæ |
09:05-09:30 | 28-I-001 | ÕÅÀñºÍ | »ùÓÚ»¯Ñ§ÉúÎïѧµÄ´´ÐÂÒ©ÎïÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
09:30-09:55 | 28-I-002 | µËºê¿ý | Small Molecule-induced Cell Fate Reprogramming | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
09:55-10:20 | 28-I-003 | Ëα¦°² | ÖØ´ó²¡¶¾²¡µ¼ÏòµÄÂÌɫũҩ»¯Ñ§Ñо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºËα¦°²£¬À´Â³»ª |
10:35-11:00 | 28-I-004 | À´Â³»ª | µ°°×Öʱ𹹵÷¿Ø·Ö×ÓÉè¼Æ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
11:00-11:25 | 28-I-005 | ³ÂÐË | ´óÄÔÌÇ»ù»¯µÄ±ê¼ÇÓë³ÉÏñ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
11:25-11:40 | 28-O-001 | Ф½¨Ï² | ½ºÔµ°°×ÈýÖØÂÝÐý½á¹¹µÄ¼ì²â·½·¨ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
11:40-11:55 | 28-O-002 | Öܽ | CCND1Æô¶¯×ÓÇø´®ÁªËÄÁ´ÌåµÄÐγɡ¢Ê¶±ðÓëת¼ÒÖÖÆ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
11:55-12:10 | 28-O-003 | ¬ÖÒÁÖ | º¬Ó«¹âµ¥Ôª[12]aneN3»¯ºÏÎïºÏ³É¼°ÆäDNAÄý¾Û¡¢·Ç²¡¶¾»ùÒòÔØÌå | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÇúÏþ¸Õ£¬ÑÕÏþ÷ |
13:30-13:55 | 28-I-006 | ÑÕÏþ÷ | µ¥ÏßÁ£Ìåˮƽ¶à²ÎÊý¸ßͨÁ¿¼ì²âµÄÐźÅתµ¼Ñо¿Ó¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
13:55-14:20 | 28-I-007 | ÇúÏþ¸Õ | ºËËáµÄ·Ö×Óʶ±ð»úÖÆ¼°ÆäÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
14:20-14:35 | 28-O-004 | ÖÜ´«Õþ | 5-Methylene Maleimides for Cysteine Bioconjugation | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
14:35-14:50 | 28-O-005 | ºØÏþÅô | ÌÇ·Ö×Ó̽ÕëµÄ¹¹½¨ÓëÈËÀàÖØ´ó¼²²¡Õï¶Ï | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
14:50-15:15 | 28-I-026 | Ñî¹â¸» | °Ð±êµ¼ÏòµÄÌìÈ»²úÎï½á¹¹ÓÅ»¯ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÁõÎÄ£¬ÕÔ×Ú±£ |
15:20-15:45 | 28-I-008 | ÁõÎÄ | ÁÖ¿ÉÃ¹ËØµÄÉúÎïºÏ³É£ºÁ½¸öС·Ö×ÓÁò´¼µÄ¹ÊÊ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
15:45-16:10 | 28-I-009 | ÑîÕñ¾ü | ÒìºËÜÕÁªºÏ2¡¯-ÍÑÑõ¼¡ÜÕÐÞÊκËËáÊÊÅäÌåAS1411,ÆäÉúÎï»îÐԺͷÖ×Óµ÷¿Ø»úÖÆÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
16:10-16:35 | 28-I-010 | Áõ¸Õ | Conmutaxol inhibits tumor metastasis through blocking NOD1/2 mediated NF-B and MAPKs signaling | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
16:35-17:00 | 28-I-011 | ÕÔ×Ú±£ | С·Ö×Óµ÷¿Ø½Íĸ֬ÖÊ´úл | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
17:00-17:15 | 28-O-007 | ÀîÀ¤ | ÏßÁ£Ìå°ÐÏòµÄSO2Ó«¹â̽Õë¼°»îϸ°û³ÉÏñ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
17:15-17:30 | 28-O-008 | ²Ü´ºÑô | ²ÎÓ뿹Ö×ÁöÒ©ÎïFR901464ÉúÎïºÏ³ÉµÄø´ß»¯»úÖÆÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
17:30-17:45 | 28-O-009 | ÕźÀ | ´´ÐÂÒ©Îï·¢ÏÖ¼°µ°°×Öʶ¯Ì¬µ÷¿ØÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
17:45-18:00 | 28-O-010 | Íõ½¨¹ú | °ÐÏòÒÒõ£ÈéËáºÏ³ÉøµÄ¿¹Ö²¡Õæ¾úÒÖÖÆ¼Á | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
2016-07-03 |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÀîÑÞ÷£¬»ÆÖ¾ç£ |
08:30-08:55 | 28-I-012 | ÀîÑÞ÷ | »ùÓÚ»¯Ñ§ºÏ³ÉÒßÃçµÄÖ×ÁöÃâÒßÁÆ·¨ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
08:55-09:20 | 28-I-013 | »ÆÖ¾ç£ | ¿¹·ÊÅÖÖ¢Ïȵ¼»¯ºÏÎïµÄ·¢ÏÖ¼°·Ö×Ó×÷ÓûúÖÆÑо¿Ïȵ¼»¯ºÏÎïµÄ·¢ÏÖ¼°·Ö×Ó×÷ÓûúÖÆÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
09:20-09:35 | 28-O-011 | Ì·¼Îºã | ÌØÒìÐÔG-ËÄÁ´ÌåÓ«¹â̽ÕëµÄ¿ª·¢ÓëÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
09:35-09:50 | 28-O-012 | ÌÀо° | Reduce off-target effect of RNA interference with circular siRNAs | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
09:50-10:05 | 28-O-013 | Íõ»¶ | ¶àëÄÌìÈ»²úÎïµÄÉúÎïºÏ³É | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÓàТÆä£¬ÑÓ |
10:20-10:45 | 28-I-014 | Ï¯Õæ | Ö§Á´PCR¸ßÐ§ÖÆ±¸»ùÒòÄÉÃ×ÔØÌå | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:45-11:10 | 28-I-015 | ÑÓ | µ¥Ï¸°û·ÖÎö | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
11:10-11:35 | 28-I-016 | ÓàТÆä | ¸ßЧ¸ßÉúÎïÏàÈÝÐÔ¾ÛºÏÎï»ùÒòÔØÌåµÄ¹¹Ð§¹ØÏµÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
11:35-11:50 | 28-I-017 | ÍõÏþ»Ô | ¶¾Æ·µÄÉñ¾ÌìÈ»ÃâÒß×÷Óü°Ò©Îï·¢ÏÖ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
11:50-12:05 | 28-O-014 | ×ÞÅô | »ùÓÚAPEX¼¼ÊõµÄ¿Õ¼äÌØÒìÐÔµ°°×ÖÊ×é±ê¼Ç | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£º½ªÖ¾ºê£¬Àî³Զ |
13:30-13:55 | 28-I-018 | ½ªÖ¾ºê | È˲ÎRNAµÄ¿¹Ðļ¡È±Ñª»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
13:55-14:20 | 28-I-019 | Àî³Զ | A molecular switch that controls oxygen-independent degradation of hypoxia-inducible factor-1¦Á | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
14:20-14:35 | 28-O-015 | Ìï›p | G-ËÄÁ´ÌåRNA×÷ΪÐÂÐÍ¿¹±û¸Î²¡¶¾°Ð±êµÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
14:35-14:50 | 28-O-016 | ÁõÏþºì | »ùÒò±àÂë·ÇÌìÈ»°±»ùËáÀ©Õ¹Ó«¹âµ°°×ÐÔÖÊ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
14:50-15:05 | 28-O-017 | λµÆ¹ú | C-kit1Æô¶¯×ÓÇøÓòG-ËÄÁ´Ìå¾§Ìå½á¹¹½Òʾ½ðÊôÀë×Ó | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ººÂС½£¬Ò¶ÐÂɽ |
15:20-15:45 | 28-I-020 | ºÂС½ | µ°°×¼¤Ã¸CÒÀÀµµÄÈÜøÌå·¢ÉúлúÖÆµÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
15:45-16:10 | 28-I-021 | Ì·Äþ»ª | °ÐÏòÑ×°©¼°Æä×ªÒÆµÄÐÂÐÍÌìÈ»»·ëÄRAsµÄ»¯Ñ§ÉúÎïѧÓë´´ÐÂÒ©Ñо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
16:10-16:35 | 28-I-022 | Ò¶ÐÂɽ | ¿¹Ö×ÁöÌÇÒßÃçÑо¿½øÕ¹ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
16:35-17:00 | 28-I-023 | Ñî²Æ¹ã | »¯Ñ§Ì½Õ롪»¯Ñ§ÉúÎïѧ´Ù½øÐÂÒ©·¢ÏÖÖ®ÇÅ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
17:00-17:15 | 28-O-018 | ÁõÌï | »ùÓÚÀ¥³æN-ÒÒõ£¼ºÌǰ·Ã¸½á¹¹µÄÒÖÖÆ¼ÁÉè¼Æ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
17:15-17:30 | 28-O-019 | Wen Zhang | The Design, Synthesis of Chirally-modified Polyamides and Their Bioactivity of Anti-tumors by Downregulating PD-1 Gene | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
17:30-17:45 | 28-O-020 | ¸ßÔ¶ | »îÌåÄÚ³¬·Ö×Ó×Ô×é×°ÓÃÓÚÖ×ÁöÕï¶ÏÖÎÁƵÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
17:45-18:00 | 28-O-021 | ÁõÎä¾ü | º¬ÀàÒìÎì¶þϩ̽Õë·Ö×Ӻϳɼ°ÆäÓëøµÄÏ໥×÷Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
2016-07-04 |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£º¾ÏŸºÏÈ£¬ÑîÕñ¾ü |
08:30-08:55 | 28-I-024 | ¾ÏŸºÏÈ | ϸ°û¹¦ÄÜ·Ö×ÓµÄÔλ³ÉÏñ¼ì²â¼°ÆäÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
08:55-09:20 | 28-I-025 | ·½Ïþºì | µ¥·Ö×ÓÓ«¹â³ÉÏñÑо¿Ò©Îï¶ÔÉöÉÏÏÙËØÊÜÌåµÄÑ¡ÔñÐÔ¼¤»î | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
09:20-09:35 | 28-O-022 | Íõ³õ | ÌìÈ»ÖвÝÒ©µÄ»¯Ñ§µ°°×ÖÊ×éѧ¼°½µÖ¬ÁÆÐ§µÄ»úÖÆÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
09:35-09:50 | 28-O-023 | ÎâÀöÄÈ | µ¥Ï¸¾úˮƽµ°°×ÖÊÏ໥×÷ÓõĸßͨÁ¿¶¨Á¿¼ì²âз½·¨ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
09:50-10:05 | 28-O-024 | Ö£Îĸ» | »ùÓÚ΢Á÷¿ØÐ¾Æ¬µÄ¶¯ÂöÖàÑùÓ²»¯Ñо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÏ¯Õ棬ÖÜÏè |
14:00-14:15 | 28-O-025 | ÒÁ³ÉÆ÷ | ºËËá±í¹ÛÒÅ´«ÐÞÊεĻ¯Ñ§²âÐò | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
14:15-14:30 | 28-O-026 | ·®ÐÂÔª | ·´Ê½»·ÐÁÏ©´¥·¢µÄ¶Ï¼ü·´Ó¦ÔÚµ°°×Öʹ¦Äܼ¤»îÖеÄÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
14:30-14:45 | 28-O-027 | ÏÄÇà | ÒÖÖÆÐÔtRNA¶Ô¶ÅÊϼ¡ÓªÑø²»Á¼¼²²¡µÄÖÎÁÆÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
14:45-15:00 | 28-O-006 | Ô¬±Ø·æ | »¯Ñ§±ê¼Ç-ÒºÏàÉ«Æ×ÖÊÆ×·ÖÎöÓÃÓÚºËËá±í¹ÛÒÅ´«ÐÞÊÎÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
15:10-15:35 | 28-I-027 | ϯ½¨ÖÒ | miR-122 ½éµ¼¸ÎÖ×Áö΢»·¾³·¢²¡»úÖÆ¼°¿¹Ö×ÁöÌìÈ»»îÐԳɷÖɸѡÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
15:35-16:00 | 28-I-028 | ½¯»ªÁ¼ | ¼ÆË㣺µ°°×Öʽṹ-¹¦ÄÜ-µ÷¿ØÑо¿µÄÖúÍÆÆ÷ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥ Ö÷³ÖÈË£ºÒ¶ÐÂɽ£¬ÀîÑÞ÷£¬ÓàТÆä£¬ÑÓ |
10:05-12:05 | 28-P-001 | Li-Ping Bai | Cardenolides as Inhibitors of Hypoxia-Inducible Factor-1 Transcriptional Activity | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-002 | ÕÅÑå·å | ʵʱ׷×ÙС·Ö×Ӻ͸߷Ö×ÓÒ©Îï׺ºÏÎïµÄÒ©ÎïÊͷŹý³Ì | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-003 | ´ÞÊ«»Û | ¼×Ëáõ¥ÐÍëÄÖ¬ÖÊÌåµÄ°±»ùËáÊýÁ¿¶Ô»ùÒòתÔËÐÔÄܵÄÓ°Ïì | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-004 | Àîçù | ºËËáËðÉËAlkBÐÞ¸´Ã¸°Ð±êÑéÖ¤ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-005 | ÖÜ¿Ïè | ÒÔD-¦Ð-AΪ»ù±¾¹Ç¼ÜµÄÓÃÓÚÄÔÄÚµí·ÛÑù°ß¿é¼ì²âµÄ½üºìÍâ̽ÕëµÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-006 | Ðí¾²âù | ÏßÁ£ÌåµòÍöͨ·Ĥµçλ½µµÍÓëϸ°ûÉ«ËØCÊͷŵÄÏ໥¹ØÏµÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-007 | Àîéª | µ¥·Ö×ÓÓ«¹â³ÉÏñÑо¿TGF-beta ÐźÅͨ·ÏÂÓε°°×Smad7µÄÒÖÖÆ»úÀí | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-008 | ¹ùµÀϼ | »ùÓÚÓ«¹â¹èÄÉÃ׿ÅÁ£Ò©ÎïÔØÌåµÄÄÍÒ©ÐÔÖÎÁÆ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-009 | ÕÅÏþ·Ò | pHÃô¸ÐµÄ¾Û¼×»ù±ûÏ©Ëá¿ÕÐÄÄÉÃ×ÇòÓÃÓÚÒ©ÎïÊͷźͳ¬Éù³ÉÏñ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-010 | »ÆÀÚ | »ùÓÚ¹âµã»÷·´Ó¦µÄMicroRNA̽ÕëµÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-011 | ºÎ²¨ | àßòßø¶þͪÑÜÉúÎïµÄºÏ³É¼°ÉúÎï»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-012 | Íõµ¤ | »ùÓÚ˫ӫ¹âËØÃ¸±¨¸æÌåϵµÄCas9»ùÒòÇиî»îÐÔ¶¨Á¿¼ì²âÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-013 | ÁõÃÈ | 4-ôÇ»ù±½¼×È©-2-°±»ùàçßò-4-¼×õ£ëêµÄºÏ³ÉºÍ±íÕ÷ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-014 | Áõ±ù | »ùÓÚDNAÕÛÖ½ÊõµÄÄÉÃ×½ð°ô¾«ÃÜÐÞÊÎ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-015 | ²ÌСÀö | ZnOÔØÒ©ÌåϵµÄ¹¹½¨¼°ÆäÔڷΰ©Ï¸°ûÕïÁÆÖеÄÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-016 | ÁõÓ¨ | PLK1¼¤Ã¸KDµÄ±ð¹¹ÒÖÖÆ¼Á | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-017 | Ô·Ç¿ÌÎ | ¾ßÓжàģʽ̽Õ빦ÄܵÄË«ºËпÅäºÏÎïÉè¼ÆºÏ³É¼°Æä¶ÔǰÁÐÏÙ°©µÄ³ÉÏñ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-018 | ÀîÁÉÁÉ | ÜÅÀàÑÜÉúÎï×÷ΪһÀàÐÂÐ͹âÉù³ÉÏñ²ÄÁϵÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-019 | ÕÅ¿Áú | Ò»ÖÖ»ùÓÚ³¤Ñ»·Ñõ»¯ÌúÄÉÃ×½ºÊøµÄ¸ßÐÔÄÜT2´Å¹²ÕñÔìÓ°¼Á | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-020 | ÕÔÒ»À× | DNAÁòÐÞÊεĽṹÓ빦ÄÜ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-021 | ºúÎıó | ͨ¹ýµã»÷»¯Ñ§·´Ó¦ÖƱ¸Î»µãÌØÒìµÄÓ«¹â¸ß·Ö×Ó-µ°°×ÖʽáºÏÌå | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-022 | Фäì | microRNAÄÉÃ׸´ºÏÎïÓÃÓÚmicroRNA°ÐÏòÔËÊä | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-023 | ÌïÌð | ÑôÀë×ÓÖ¬ÖÊÌåÓë»ùÒò¸´ºÏÎïµÄ½áºÏ¶¯Á¦Ñ§ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-024 | ºúÌÎ | DPIʵʱ̽Ë÷A¦Â1-42ºÍLilrb2 receptorÏ໥×÷Óõ͝Á¦Ñ§»úÖÆ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-025 | Hua Chen | Synthesis of tetracyclic iminosugar derivatives fused thiazinan-4-one as potential HIV-RT inhibitors | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-026 | ÇúÈÊÓå | ÐÂÐÍà×à¤Àà·´¿¹ÐÔAHASÒÖÖÆ¼ÁµÄÉè¼Æ¡¢ºÏ³ÉÓëÉúÎï»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-027 | Íõ¼Ñç÷ | »ùÓÚBst ¾ÛºÏø¶¨Á¿ÆÀ¹ÀDNAºÍRNAÖеÄm6A | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-028 | Áõ½¨¾ü | ÖÇÄÜÏìÓ¦ÐÍ΢½ºÄÒÔÚϸ°ûÄڵĿØÖÆÊÍ·ÅÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-029 | ¼ÍîÚ | Ë®ÈÜÐÔ¹²éî¾ÛºÏÎï×÷Ϊģ°æºÏ³É½ðÄÉÃ׿ÅÁ£ÔÚ¹âÉù³ÉÏñÖ¸µ¼ÏµÄÕïÁÆÒ»Ì廯 | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-030 | Íõѩӱ | ÉúÎïºÏ³É¸¨Ã¸ÀàËÆÎï | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-031 | ÁõÓñÑ© | ɸ²éÑõ»¯»¹Ôø¸¨Òò×ÓÆ«ºÃÐÔÏà¹ØµÄÍ»±äÈȵã | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-032 | ÐìËÄ´¨ | ×ó±½±û°·ÔÚ¶à°Í°·µÚÈýÊÜÌåͨµÀÖд«Êä | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-033 | Ñî½Ü | Ò»ÖÖº¬ßÁົ·õ£ë껯ºÏÎïµÄºÏ³É¡¢±íÕ÷¼°ÆäÓëCT-DNAµÄÏ໥×÷Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-034 | ÍòȺ | Ó¦ÓÃÖÐ×ÓÑÜÉä¼¼ÊõÑо¿ÌÇÜÕøµÄÖÊ×Ó»¯×´Ì¬ºÍÇâ¼üÍøÂç | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-035 | ÍõÓîçù | Cathepsin BÏìÓ¦µÄÈÜøÌå°ÐÏòÓ«¹â̽Õë¼°ÆäÔÚϸ°û³ÉÏñÖеÄÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-036 | ºÎÊ¢±ó | ÄÍÒ©ÐÔÖÊÁ£½ÓºÏ´«µÝЧÂʵĸßÁéÃô¡¢¿ìËÙ¶¨Á¿¼ì²â | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-037 | ÀîÖ¾ÔË | »ùÓÚº¬ÌǾۺÏÎï±ÈÂÊÓ«¹âpH̽ÕëµÄºÏ³É | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-038 | ÆîºÀÂü | ²»Í¬Ö²ÎïÒÒõ£ôÇËáºÏ³ÉøÑÇ»ù¼äÏ໥×÷ÓõÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-039 | ÕÅÓªÓª | ÒÒõ£ôÇËáºÏ³Éø½á¹¹Ñо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-040 | Òü¾ü | ÝÁ¶þ¼×õ£Ñǰ·Îª¹Ç¼ÜµÄÓ«¹â̽ÕëÔÚ»îϸ°ûÈÜøÌåÖÐÑ¡ÔñÐÔºÍÌØÒìÐÔ¼ì²â¹Èë׸ÊëÄ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-041 | ÍõÑå¶÷ | Synthesis of fluorescent bisboronic acid compounds and their recognition to Lewis oligosaccharides | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-042 | ÍõÅô³å | ÀûÓÃAPEXʵÏÖ»îϸ°ûÖпռäÌØÒìÐԵĵ°°××éѧ±ê¼Ç | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-043 | Áõ¼Ñ´º | Synthesis and the Interaction of 2-(1H-pyrazol-4-yl)-1H-imidazo[4,5-f][1,10]phenanthrolines with Telomere DNA as antitumor agents | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-044 | ÖÜÓ± | »ùÓÚAPEX¼¼ÊõµÄºËËữѧ±ê¼Çз½·¨ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-045 | Âí¸Õ | µí·ÛÑùµ°°×ÏËά΢¹Û½á¹¹µÄºìÍâ¹âÆ×·ÖÎö | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-046 | ÕÔ»Ý | ¸ßЧ˫¹â×Ó¼¤·¢¿É½µ½âµÄ½»Ìæ¹²¾ÛÎï×Ô×é×°ÄÉÃ×¾Û¼¯Ìå | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-047 | ÁõÕÜ | ¸´ºÏ¾Ûõ¥ÄÉÃ×̽ÕëÔÚ°ÐÏòÒ¶ËáÊÜÌåµÄ»îÌå¹âÉù³ÉÏñÖеÄÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-048 | ÀîТÃô | Ë«ºË½ð£¨¢ñ£©ì¢ÀàºÍ¶þÁò´ú°±»ù¼×ËáÑÎÅäºÏÎïµÄÓ«¹âºÍÌåÍ⿹°©»îÐÔ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-049 | ´ÞÖ¾ÉÁ | µªÔÓß¹à¤ÑÜÉúÎï×÷ΪEGFRºÍSrcÒÖÖÆ¼ÁµÄÉè¼ÆºÏ³ÉÓ뿹°©»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-050 | ÐìÔÆÁú | 3ÖÖ³¤ÑæÃºÓë΢ÉúÎïµÄÈÜúƥÅäʵÑéÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-051 | Âíç÷ | »ùÓÚDNAÔÓºÏË®Äý½ººÍȾÁϵÄSNP¿ÉÊÓ»¯Ó«¹â¼ì²â | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-052 | Ñî¼ÎÀö | Ä©¶ËάÉúËØEÐÞÊÎsiRNA¶Ô»ùÒò±í´ïµÄ¹âµ÷¿Ø | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-053 | ÍõÊéÏã | ·¦ÑõºÍ¹âÕÕË«¿ØµÄÐÂÐÍÕï¶ÏÖÎÁÆÇ°-ǰҩµÄ¹¹½¨ÓëÌåÍâϸ°û¶¾ÐÔÆÀ¼Û | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-054 | ÁÖãüÓò | °ÐÏò»¯Ñ§Æ½Ì¨T-REXµÄ¹¹½¨¼°ÆäÔÚÑõ»¯»¹ÔÐźÅͨ·Ñо¿·½ÃæµÄÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-055 | ÐìÖ¾±ó | Pleuromutilin derivatives: From antibiotics to antidiabetics | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-056 | °²îÚÀ¤ | ÀûÓÃClick½»Áª·´Ó¦ÒýÈëÅäÌåGAlNAcÒÔ¶ÔsiRNA½øÐй¦ÄÜ»¯ÐÞÊÎ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-057 | ¹ùäì¼Ñ | ÉßÂéͪ¼°Í¬ÏµÎïÒìÔ´ÉúÎïºÏ³É;¾¶¹¹½¨ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-058 | ºî¾²Àö | С³¦°ÐÏòÊÍ·ÅNO¹©Ìå¼°Æä´ÙÒ©ÎüÊÕµÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-059 | ֣˹Æë | ÀûÓõ°°×Öʼ¤»î²ßÂÔÑо¿MAPKͨ·µÄÐźŴ«µÝ¹ý³Ì | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-060 | »ÆÓ | »ùÓÚÉúÎïºÏ³ÉºÍºÏ³É»¯Ñ§µÄÌìÈ»²úÎïÒ©Îï·¢ÏÖºÍÑÜÉú | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-061 | κ·æ | Æ«Õñ·Ö±æºÍƵÕñ¶¯¹âÆ×ϵͳ£ºÒ»¸ö¶àÓÃ;µÄ½çÃæºËËá½á¹¹Ó붯Á¦Ñ§¼ì²âƽ̨ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-062 | ÍõÊØ·æ | ÁòÁ´Ë¿¾úËØÉ±Ãð°ûÄÚ¼ÄÉú¾úµÄ×÷ÓûúÖÆ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-063 | ²ÌÓî | ßÁ¿©²¢ßÁ¿©¶þͪÔÚÖ×Áö¹âÕïÁÆÉϵÄÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-064 | ³ÂÑ©Èð | ˳²¬+À×ÅÁÃ¹ËØ/3-¼×»ùÏÙàÑßÊ»ìºÏÒ©Îï¶ÔHeLaϸ°û×ÔÊɵÄÓ°Ïì | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-065 | ÕÅ´ä | Mn-TAT-PTD-NgbµÄÉñ¾±£»¤×÷ÓÃÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-066 | Áõµ¤µ¤ | ¶àÖÖÊôµÄÔ߲߸ÔÑõ»¯Ã¸µÄ¶¯Á¦Ñ§ÐÔÖÊÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-067 | ÀîÔÃÇà | ±ú¹û»¨½·õ£°·¼°ÀàËÆÎïµÄºÏ³ÉÓ뿹ѪС°å¾Û¼¯»îÐÔÆÀ¼Û | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-068 | ³Â³É | °ÐÏòÐÔsiRNAÄÉÃ׸øÒ©ÌåϵµÄ¹¹½¨ºÍ±íÕ÷ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-069 | ÓÚÃ÷À¤ | 4-¼×Ñõ»ù±½¼×È©-4-ôÇ»ù±½ÒÒõ£ëêµÄºÏ³É¼°Óëct-DNAµÄÏ໥×÷Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-070 | лФ | ²¶×½µ°°×-µ°°×Ï໥×÷ÓõÄË«¹¦ÄÜ̽Õë | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-071 | ³µÍ¨ | ¶ËÁ£G-ËÄÁ´ÌåÅäÌ壺ÌìÈ»²úÎïSchizocommuninÑÜÉúÎïµÄÉè¼Æ¡¢ºÏ³ÉÓëÆÀ¼Û | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-072 | ½ªÎõ | »ùÓÚÀ¥³æ¼¸¶¡ÖÊø½á¹¹µÄÒÖÖÆ¼Áɸѡ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-073 | Õű̲¨ | Ò»ÖÖÓÕµ¼µ°°×·ºËØ»¯½µ½âµÄ°Ðµ°°×Ë®½âëIJßÂÔ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-074 | ÑîìÚ | ¾ßÓÐÖÊÆ×±êÇ©×ªÒÆ¹¦ÄܵĹ⽻Áª | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-075 | Íõ˼¼Ñ | Formation and Stabilization of The Human Telomeric Repeats-Containing RNA G-quadruplex by Benzothioxanthene Derivatives with Anti-tumor Activity | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-076 | ÀîÊ«Á¼ | À´Ô´ÓÚÌìÈ»²úÎïµÄÐÂÐͳ¤Ð§DPP-4ÒÖÖÆ¼ÁµÄ·¢ÏÖºÍÉè¼Æ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-077 | Íõ²Êϼ | ÏßÁ£ÌåÄÚ¹Èë׸ÊëıÈÀýÓ«¹â³ÉÏñ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-078 | Î̽ðÅô | DNAzyme½»ÁªË®Äý½ºµÄÖÆ±¸¼°ÆäÔÚÆÏÌÑÌǼì²âÖеÄÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-079 | ÑîË®À¼ | ΢ÉúÎïÈܽâÄÚÃɹźÖúӰÏìÒòËØ¼°²úÎï·ÖÎö | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-080 | ³Âçù | ÐÂÐ͵ÄË«µ×ÎïÀàËÆÎïµÄ¼¸¶¡ÖʺÏøÒÖÖÆ¼ÁÉè¼Æ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-081 | ÓÚÓ¾·É | O-Á×õ£»¯Ë¿°±ËáÑÜÉúÎïÖÆ±¸¼°»úÀíÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-082 | ³É÷ | Screening of Antitumor Activity of the Novel Phenanthroline Derivatives | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-083 | Åí·É | »ùÓÚ¹èÄÉÃ×ÏßµÄÒ©ÎïÔØÌå½øÐа©Ö¢ÖÎÁÆ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-084 | ÖÜÑ×·é | »ùÓÚÐãÀöÒþ¸ËÏß³æµÄÓ«¹â¹èÄÉÃ׿ÅÁ£µÄ¶¾ÐÔÆÀ¼Û¼°°ÐÏò·Ö×Ó³ÉÏñÓ¦ÓÃÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-085 | ³Âѧ»Ý | º¬ÈýßòµÄºËËá°ÐÏò¿¹°©Ò©ÎïµÄºÏ³É¼°»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-086 | Uzair Alam | Synthesis of Zidovudine derived [12]aneN3 Compounds and Their Interaction with DNA | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-087 | ³Â»áÓ¢ | ¿Ç¾ÛÌǽÓÖ¦PEI·Ç²¡¶¾»ùÒòÔØÌåµÄ¾ùÏàºÏ³É¼°Æä»ùÒòתȾ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-088 | ÕÅÑÇ¸Õ | ÖÐÒ©Ó뻯ѧ-ÖвÝÒ©µÄδÀ´ÓëÌôÕ½ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-089 | Àî½ð²¨ | ΢СºËÌǺËËáµÄ»¯Ñ§·Ö×Ó̽Õë | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-090 | Ç®ÒæÆ½ | Ñõ»¯¶þßòÓ«¹â̽ÕëÔÚѪÎü³æ³É³æÖгÉÏñ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-091 | Íõ½Ü | îٽ鵼µÄÉúÎïÕý½»¶Ï¼ü·´Ó¦µÄ¿ª·¢¼°Ó¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-092 | Íõ×ÓºÌ | Bcl-2¼Ò×åµ°°×½áºÏÒÖÖÆ¼ÁµÄºÏ³ÉºÍÓÅ»¯ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-093 | Íõµ¤Àû | Fe@Fe3O4ÄÉÃ×Á£×ÓÔÚMRI/´ÅÈÈÖÎÁÆÖеÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-094 | ÑîÊËÆ½ | ¶à¹¦ÄÜ´ÅÐÔÄÉÃײÄÁÏÔÚÖ×ÁöÕïÁÆÒ»Ì廯ÖеÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-095 | Àî¿Ë½¨ | ÒÒõ£¸¨Ã¸AôÈ»¯Ã¸³ý²Ý¼ÁµÄ¿¹ÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-096 | ¶¡ÉÛÕä | EcoSynther¡ªE.coliÉúÎïºÏ³ÉDZÁ¦ÍÚ¾òÄÜÊÖ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-097 | ÂÀ½£À¥ | Õë¶ÔFLT3¼°ÆäÍ»±äµÄµûà¤ÍªÀàÒÖÖÆ¼ÁµÄÓÅ»¯Éè¼Æ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-098 | Ðì¿Ë»¨ | ÑÇÎøËáÄÆÓÕµ¼Ö×Áöϸ°ûµòÍö¹ý³ÌÖÐÎø´¼ºÍ¹ýÑõ»¯ÇâµÄͬʱ¼ì²â | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-099 | ³Âº£Ñó | µÚÈý´úEGFR-T790MÒÖÖÆ¼ÁµÄ·¢ÏÖÓëÓÅ»¯ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-100 | ÁõÑ×¾þ | ¶àÖÖ¾ßÓÐÉñ¾ÓªÑø»îÐÔµÄÁ×Ö¬õ£ÌÇÜյĸ·¨ºÏ³É | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-101 | Áõΰ | Ò°ÉúÓ£ÌÒÀîÒ¶ÒÖÖÆ¦Á-ÆÏÌÑÌÇÜÕø»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-102 | ºÎµ¤ | conditionally disordered chaperones confer programmed specificity to defend stress | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-103 | ²ÌÀû·æ | ÀûÓöàëÄÆ¬¶ÎÏ໥×÷ÓòßÂÔÑо¿¶¯Ì¬½á¹¹±ä»¯µ°°×ÖʵķÖ×Ó×÷ÓÃȫò | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-104 | »Æ¸ÕÁ¼ | ¶àÌǵÄÑÜÉú»¯·½·¨¼°ÉúÎï»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-105 | ·®æÃæÃ | »ùÓÚÑõ»¯Ê¯Ä«Ï©¿ÉÊÍ·ÅÐÍÊÊÅäÌåDNAÉúÎï´«¸ÐÆ÷ÐźŷŴó¼ì²âATP | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-106 | ÍõÓñÇà | NM23-H2/G4×è¶Ï¼Á£ºIsaindigotoneÀ໯ºÏÎïµÄÉè¼Æ¡¢ºÏ³É¼°ÆÀ¼Û | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-107 | ÍõÀÚ | ɸѡ·ÇÌìÈ»¸¨Òò×Ó¸ßЧתÔ˵°°× | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-108 | ÁõÏòÈÙ | ÈÈ´ø¼ÙË¿½Íĸ¾úÈܽâÉñ¸®ÃºµÄʵÑéÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-109 | ֣ͩ | С·Ö×ÓÆÆ»µE3½ÓÍ·µ°°×SPOP-µ×ÎïÏ໥×÷ÓÃÓëÉö°©ÖÎÁÆ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-110 | ÁÎÑÞ¾ê | ÄÉÃ×Cu2O¹â´ß»¯É±¾úµÄÔλÈȶ¯Á¦Ñ§Ñо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-111 | Öì´óDZ | NADPHÑõ»¯Ã¸(NOX)ÒÖÖÆ¼Á»·¶þ·¼»ùµâæfÑεĿ¹Ö×ÁöÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-112 | ÍôÏþƽ | ÖØÒªÄ£ÄâÌìȻҽҩÖмäÌå4-±½»ù-2-¼×»ù-5-Ñõ-Âðßø-3-ôÈËáµÄÖÆ±¸¼°Æä»¹Ô·´Ó¦ÐÔ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
»á³¡£º×ۺϽÌѧ1ºÅÂ¥ |
10:05-12:05 | 28-A-001 | Íô¸£Òâ | ÖÐÒ©»îÐԳɷÖÓ«¹â̽ÕëµÄ¹¹½¨ºÍ³ÉÏñÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-002 | Âí¼Ñ»Û | ÌìÈ»»ÆÍªÀàMAGLÒÖÖÆ¼ÁµÄ·¢ÏÖ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-003 | ¸¶Ó¢½Ü | Ò©ÎïÓëÄÉÃ×½ð²»Í¬Á¬½Ó·½Ê½µÄ±È½Ï¼°Æä¿¹°©»îÐÔµÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-004 | Ò¶×Ó | ²»¿ÉÄæµ°°×¼¤Ã¸ÒÖÖÆ¼Á°Ð±êµ°°×µÄ»¯Ñ§µ°°×ÖÊ×éѧ·ÖÎö | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-005 | ÐÏÑÞÁá | ½ª»ÆËØ-à×à¤ÍªÔÓºÏÌåµÄºÏ³É¼°ÉúÎï»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-007 | ÀîÑÇʤ | ÍÂ̼ٵ¥°û¾úÐÂÐÍȺÌå¸ÐÓ¦ÐźÅIQSÀàËÆÎïµÄÉè¼Æ¡¢ºÏ³ÉÓë»îÐÔ³õ̽ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-008 | ³ÂÓ° | Ç×µçÖ¬ÖÊ·Ö×ÓÐÞÊÎλµãµÄ¶¨Á¿»¯Ñ§µ°°×ÖÊ×éѧÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-010 | ÆëлÃô | ת»ùÒòÃ޺ͳ£¹æÃÞÖÖÖ²µØÍÁÈÀÕæ¾úȺÂä¶àÑùÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-011 | YuchaoYao | Synthesis of water soluble triphenylethylene-coumarin hybrids bearing 2-oligoethoxy ethanamine side chain end-labeled with tertiary amino groups | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-012 | ÈÄˬ | DNA¼×»ù»¯¶àλµã¼ì²â | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-014 | Òü¾ü | Ò»ÖÖ»ùÓÚµ¤»Çõ£ÂȵÄÁò»¯ÇâÓ«¹â̽Õ뼰ϸ°û³ÉÏñÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-015 | ËλÀȨ | ßÁßòÒøÅäºÏÎïµÄ¿¹Ö×ÁöÐÔÖÊÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-016 | ÍõÁ¦ | [Mo36O108(NO)4(H2O)16].52H2OµÄºÏ³É¼°Æä¶ÔÀÒ°±ËáøµÄÒÖÖÆ×÷Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-017 | ÂÞȺ | ¾ßÓÐʱ¼ä·Ö±æÓ«¹âÌØÐÔµÄÉúÎï»îÐÔÓ«¹â̽Õë¼°ÆäÔÚϸ°û³ÉÏñÖеÄÓ¦Óà | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-018 | ³ÂÓñÄÈ | MDM2 and scorpion active peptide BmK AGP-SYPU2 mode of action prediction | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-019 | ÀîÐÄê¿ | Ò½Óø߷Ö×Ó/HAÈýÔª¹ÇÖ²ÈëÌ帴ºÏ²ÄÁϵÄÖÆ±¸ÓëÐÔÄÜ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-021 | ËÎÏþÁÕ | ¼¸ÖÖÊÐÊÛ½ÍËØµÄ¿¹Ñõ»¯ÄÜÁ¦µÄ±È½Ï | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-022 | ÇØÎª | ¶¨Á¿µ°°×ÖÊ×éѧ½ÒʾO-GlcNAcÐÞÊÎÎȶ¨Æäµ×Îïµ°°× | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-023 | ÕÅÝí | ÏßÁ£ÌåºôÎüÁ´¸´ºÏÎïµÄ½á¹¹Óë×÷ÓûúÀíÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-024 | ÂíѩƼ | ¸ßÁéÃô¸ßÌØÒì¿ÉÊÓ»¯¼ì²âHIV²¡¶¾µÄÄÉÃ×¼ì²â¼¼Êõ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-025 | ÁõæÃæÃ | »Ç´ïÀàËÆÎïRrt1.17µÄ±íÕ÷¼°ÆäÌåÄÚ¿¹ÑªË¨»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-026 | Íõ¿µ | Á½ÖÖÈËÔ´ÒÒõ£µ¨¼îÊÜÌåÑÇÐÍÆÀ¼ÛÄ£Ð͵Ĺ¹½¨ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-027 | κЦ | µªÔÓÌÇÐÞÊεÄÝÁ¶þõ£Ñǰ·ÀàÑÜÉúÎïµÄÉè¼Æ¼°ºÏ³É | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-028 | ´÷½¨Òµ | »ùÓÚ»¯Ñ§µ°°×ÖÊ×éѧµÄ»ÆÜËÜÕ¿¹¸ÎÔàÖ¬·¾»¯»úÖÆÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-029 | ºúÏþÃ÷ | ÐÎ̬¿Éµ÷¿ØµÄÓ«¹âÄÉÃ×Á£×ӵĺϳɣ¬¹âÎïÀíÐÔÖʼ°ÆäË«¹â×Óϸ°û³ÉÏñ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-030 | ÅíÊ¥Ã÷ | Design, synthesis, advanced glycation end-products and ¦Á-glucosidase inhibition in vitro of diosmetin derivatives | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-031 | ·¶±üÁÕ | Á×îâÀ¶×÷Ϊ¹âÆ×̽ÕëÊÔ¼Á²â¶¨ÁòÆÕÂÞÄþ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-032 | Íõ½ðÌÎ | °±¼×õ£»ù¸Ê¶ÌÇÐÞÊÎÝÁõ£Ñǰ·ÑÜÉúÎïµÄºÏ³É | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-033 | ËθßÅô | ËÄÇâÒìàßøÑÜÉúÎï×÷ΪPDE4ÒÖÖÆ¼ÁµÄÉè¼Æ¡¢ºÏ³É¼°ÉúÎï»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-034 | ÀîºìÑà | °åÀõ¶àÌÇ-ÎøÄÉÃ×Á£×Ó¸´ºÏÎïµÄÖÆ±¸¡¢±íÕ÷¼°¿¹Ö×Áö»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-035 | ³Â±ò | °±¼×»ùßßà¤ÑÜÉúÎïÐÞÊÎË«ÝÁõ£Ñǰ·»¯ºÏÎïµÄºÏ³É | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-036 | ÇØÃúÔó | »ùÓÚ°±»ùà×ऽṹµÄEGFR T790MÒÖÖÆ¼ÁÉè¼Æ¼°»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-037 | ½ªÖ¾»Ô | »¯ºÏÎïµÄ¿¹Î¢ÉúÎï»îÐÔÃâ·Ñɸѡƽ̨:CO-ADD | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-038 | ÀîÏòÈÙ | L-¿¹»µÑªËᣬ¦Á-ÉúÓý·Ó£¬Ô»¨ÇàËØB3£¬¦Â-ºúÂܲ·ËغÍϺÇàËØÓëÈܾúøÏ໥×÷ÓûúÖÆÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-039 | ÌÆ¾ýÔ´ | 1,3,4-àç¶þßòϯ·ò¼îÀÒ°±ËáøÒÖÖÆ»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-040 | Òü¾ü | IR-780Ñ¡ÔñÐԵļì²â2 - °±»ù±½Áò·Ó | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-041 | ÈÖÈðÑ© | ÊÖÐÔ°±»ù´¼ÐÞÊÎÝÁõ£Ñǰ·ÑÜÉúÎïµÄ¿¹Ö×ÁöÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-042 | Li Wu | Nucleotide incorporation across from templating L-nucleoside by DNA polymerases | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-043 | ãÆÏþ¸Ù | ÌìÈ»ASIC3/ASIC1aÑ¡ÔñÐÔÒÖÖÆ¼ÁµÄ·¢ÏÖ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-044 | ÕÔÖÞ | Ò»ÖÖÐÂÐÍturn-onÓ«¹â̽ÕëÓÃÓÚ¼ì²âÈý±½»ùì¢ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-045 | ¶´¨ | ÐÂÐͱ½²¢àçßòÑÜÉúÎï×÷ΪpHÓ«¹â̽ÕëÓ¦ÓÃÓÚϸ°û³ÉÏñ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-046 | Ò¦¸ê | ÓóÂݶ¾ÏÙ¹Üת¼×é²âÐò×é×°¼°¶¾Ëغϳɹ¦Äܵ°°×·ÖÎö | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-047 | ÁõƽÏÈ | CYP119øͻ±äÌå¶Ô˳ʽ-b-¼×»ù±½ÒÒÏ©ÀàËÆÎï²»¶Ô³Æ»·Ñõ»¯·´Ó¦µÄÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-048 | ³ÂÍþ | »ùÓÚNAG ¨CthiazolineµÄ84¼Ò×åÌÇ»ùË®½âÃ¸ÌØÒìÐÔÒÖÖÆ¼ÁµÄÉè¼Æ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-049 | Íõð¥Àö | ±´úÍéÌþÍѱøµÄÑ¿°û±íÃæÕ¹Ê¾¼¼ÊõÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-050 | ¿µ¶«Î° | First Discovery of Novel 3-Hydroxy-quinazoline-2,4(1H,3H)-diones as Anti-Vaccinia and Adenovirus Agents via ¡°Privileged Scaffold¡± Refining Approach | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-051 | ³Ìö¦ | Óлú·Ö×Ó¶ÔRNAµÄ½µ½âºÍ¹¦ÄÜÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-052 | Ñîçù | »ùÒòÃÜÂë×ÓÀ©Õ¹¼¼Êõͨ¶Áµ¥»ùÒòÒÅ´«²¡µÄ½Ø¶Ìµ°°× | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-053 | Àîäì | »ùÓڰеã½á¹¹µÄÐÂÐÍDAPYÀàHIV-1 NNRTIsµÄÉè¼Æ¡¢ºÏ³É¼°»îÐÔÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-054 | ¸ßƼ | ÐÂÐÍßÁà¤æéà×à¤ÍªÀàÑÜÉúÎïµÄÉè¼Æ¡¢ºÏ³ÉÓëÉúÎï»îÐÔÆÀ¼Û | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-055 | ³ÂÀÚ | »ùÓÚÀ¥³æÌÇ»ùË®½âøµÄÒÖÖÆ¼Áɸѡ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-056 | ÆëΰÄÐ | »ùÓÚ½ðÄÉÃ״صÄÉúÎï°·Ó«¹â¼ì²â | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-057 | ½ººÅô | Ñõ»¯ï¯¹è½º¸´ºÏÕûÌåÖùÔÚÏß¹ÌÏàÝÍÈ¡-ÖÊÆ×·ÖÎöÓÃÓÚÐÞÊκËÜյķÖÎö | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-058 | »Æ²®ÊÀ | »ùÓÚÓÅÊÆ½á¹¹Æ¬¶ÎºÏÀí×éºÏµÄ·Ö×ÓÔӺϲßÂÔ·¢ÏÖHIV-1ÒÖÖÆ¼Á | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-059 | °²Ïþ¸Õ | »ùÓÚ½ðÄÉÃ״صľ«°·µçÖ»¯Ñ§·¢¹â£¨ECL£©¼ì²â | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-060 | Фçñ | Ò»ÖÖ»ùÓڹ⼤»îÊÊÅä×ÓÓ«¹â¼ì²â°©Ö¢²¿Î»µÄ·½·¨ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-A-061 | Ðܾü | »¯Ñ§ÑÜÉú-ÖÊÆ×·ÖÎöÓÃÓÚDNAºÍRNAÖÐôǼ׻ùºÍÈ©»ù°ûà×à¤ÐÞÊεĸßÁéÃô·ÖÎö | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-113 | ¸»²©Ê¶ | 6-¼×»ùÏÙàÑßʵÄÁ¦³¡¹¹½¨¼°·Ö×ÓÄ£Äâ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-114 | ³ÂÓñç÷ | »ùÓÚ´¸Í·×´ºËø½á¹¹µÄmiRNA-221º£Ãà±í´ïÔØÌåµÄ¹¹½¨¼°ÆäÐÔÄÜÑо¿ | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-114 | ËÎÑàÑà | pH¶ÔС·Ö×Óµ÷¿ØÄýѪø»îÐÔʵÑéµÄÓ°Ïì | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |
10:05-12:05 | 28-P-115 | ÅíË« | Ó¦ÓÃÓлú¿ò¼Ü²ÄÁϼì²âmicroRNA | Ìí¼Óµ½ÎÒµÄÈÕ³Ì |